List of Excipients in Branded Drug ENDARI

« Back to Dashboard

ENDARI Excipient Strategy and Commercial Opportunities: Formulation, Exclusivity, Patents, and Generic Risk

Last updated: September 24, 2026

ENDARI is an FDA-approved oral powder containing L-glutamine for reducing acute complications of sickle cell disease in adults and pediatric patients aged 5 years and older. Its commercial formulation is unusually simple: the product is essentially pharmaceutical-grade L-glutamine supplied in single-dose packets, without a conventional excipient platform identified in the FDA prescribing information. That simplicity reduces manufacturing complexity but also limits formulation differentiation.

The strongest commercial opportunities are pediatric taste masking, unit-dose convenience, adherence packaging, ready-to-use dispersions, global supply, and lifecycle management. The principal competitive threat is an L-glutamine generic or 505(b)(2) product that matches the active ingredient while improving palatability, dose flexibility, or administration.

What is ENDARI and how is it formulated?

ENDARI is a prescription oral powder containing L-glutamine. Emmaus Life Sciences developed and commercialized the product under FDA NDA 209053. The FDA approved ENDARI on July 7, 2017, for patients aged 5 years and older with sickle cell disease. The recommended dose is weight-based and generally ranges from 5 grams to 30 grams per dose, administered twice daily [1].

ENDARI composition and dosage form

Attribute	ENDARI specification
Active ingredient	L-glutamine
Dosage form	Oral powder
Strength	5-g packets
Administration	Mixed with food or beverage before administration
Approved population	Adults and pediatric patients aged 5 years and older
Approved indication	Reduction of acute complications of sickle cell disease
FDA application	NDA 209053
Sponsor	Emmaus Life Sciences
Approval date	July 7, 2017

The prescribing information describes L-glutamine as the active ingredient and does not identify a conventional inactive-excipient system such as a sweetener, flavor, binder, disintegrant, or suspending agent [1]. This creates a clear formulation profile: ENDARI is primarily a dose-delivery and packaging product rather than a complex excipient-enabled drug-delivery system.

What excipient strategy does ENDARI use?

ENDARI uses an excipient-minimal strategy. The product’s commercial value depends on the quality, particle properties, packaging, and administration instructions for L-glutamine rather than on a proprietary excipient combination.

Advantages of the current excipient strategy

An excipient-free or excipient-minimal powder can provide:

• Lower formulation complexity
• Fewer excipient-related safety concerns
• Reduced compatibility testing
• Simpler regulatory documentation
• Easier scale-up and contract manufacturing
• Lower risk of excipient shortages
• Greater flexibility for global markets with different excipient restrictions

The strategy is well suited to a high-dose amino-acid product. Because patients receive grams of L-glutamine rather than milligram quantities of a potent small molecule, excipients could materially increase sachet mass and complicate administration.

Limitations of the current strategy

The same approach creates several commercial weaknesses:

• L-glutamine has a large dose burden.
• The powder can be difficult to disperse uniformly.
• Taste and mouthfeel can affect pediatric adherence.
• The product requires preparation before administration.
• Fixed 5-g packets reduce dose flexibility.
• A simple composition may offer limited composition-of-matter differentiation.
• Generic manufacturers may be able to reproduce the basic formulation with limited technical investment.

The formulation therefore has a low barrier to substitution unless manufacturing controls, particle engineering, packaging, stability, or clinical-use patents create additional protection.

What formulations could improve ENDARI?

The most commercially relevant formulation opportunities are not conventional excipient substitution alone. They involve improving administration, palatability, dosing accuracy, and adherence.

Taste-masked powder

A taste-masked powder could use a permitted sweetener, flavor system, coating technology, or microencapsulation approach. The principal target population would be children aged 5 years and older, although adolescents and adults with chronic treatment burdens could also benefit.

Potential technologies include:

• Flavor-modified powder
• Lipid or polymer-coated L-glutamine particles
• Granules designed for rapid dispersion
• Multiparticulate sachets
• Effervescent or flavored dispersible systems
• Food-compatible dry blends

A taste-masked product could support a 505(b)(2) strategy if it relies on a clinically relevant formulation change and provides new labeling or administration benefits. It would not automatically prevent an ANDA referencing the original product.

Ready-to-use liquid or suspension

A premeasured liquid or suspension could remove the need to mix ENDARI before administration. Commercial benefits would include improved convenience in hospitals, schools, home-care settings, and pediatric households.

The principal technical barriers would be:

• Chemical stability of L-glutamine in aqueous media
• Microbial control
• Sedimentation or caking
• Container compatibility
• Refrigerated or controlled-temperature storage
• Shipping weight and cost
• Shorter in-use stability after opening

A dry powder for reconstitution may offer a better balance between convenience and stability than a ready-to-drink product.

Flexible-dose packaging

The current 5-g packet architecture aligns with weight-based dosing but can create administration burdens. Commercial alternatives include:

• 2.5-g packets
• 10-g packets
• Multi-dose bottles with a calibrated scoop
• Stick packs
• Sachets organized by patient weight
• Blistered daily dose cards

Dose flexibility could improve use in pediatric patients and simplify transitions as body weight changes.

Hospital and specialty-care packaging

Institutional packaging is a separate opportunity. Unit-dose cartons, barcode-ready packets, tamper-evident packaging, and pharmacy-prepared administration kits could address hospital and specialty-pharmacy workflows.

These improvements may be protectable through packaging patents, but packaging claims generally provide narrower protection than formulation or method-of-use claims.

What patents protect ENDARI?

ENDARI’s protection is likely divided among method-of-use patents, formulation or manufacturing patents, and regulatory exclusivity. The active ingredient, L-glutamine, is a long-established amino acid and is not protected by new chemical entity exclusivity.

Publicly associated U.S. patent families have included Emmaus patents directed to the use of L-glutamine in sickle cell disease and related treatment methods. Patent coverage must be evaluated by claim scope, terminal disclaimers, patent-term adjustment, and Orange Book listing status rather than by patent count alone.

Patent and exclusivity framework

Protection category	ENDARI relevance
New chemical entity exclusivity	Not available for L-glutamine
Orphan-drug exclusivity	Seven years from FDA approval, subject to the approved indication
Pediatric exclusivity	No broadly documented six-month extension should be assumed without an FDA-recognized qualifying study
Method-of-use patents	Potentially important for sickle-cell-disease treatment claims
Formulation patents	Potentially available for taste masking, particle engineering, and dispersions
Manufacturing patents	Potentially available for purity, particle size, crystallinity, and scale-up
Orange Book patents	Must be evaluated in the current FDA Orange Book for NDA 209053
Biosimilar pathway	Not applicable; L-glutamine is a small molecule

Known patent families associated with L-glutamine treatment of sickle cell disease include U.S. Patent No. 8,609,676 and related continuation or divisional activity. The commercial value of such patents depends on whether claims cover the approved indication, dosing regimen, patient population, or a narrower technical feature. A generic applicant may challenge listed patents under Paragraph IV of the Hatch-Waxman Act.

When did ENDARI lose orphan exclusivity?

ENDARI’s seven-year orphan-drug exclusivity period began with FDA approval on July 7, 2017 and generally reached its statutory end on July 7, 2024, absent a qualifying extension or regulatory event [1, 2].

Orphan exclusivity prevented FDA approval of another drug for the same orphan indication during the exclusivity period, subject to statutory exceptions. It did not prevent all possible L-glutamine products, nor did it block products directed to materially different indications.

After orphan exclusivity, the principal barriers to generic entry are:

1. Listed patents and patent litigation.
2. ANDA bioequivalence and pharmaceutical-equivalence requirements.
3. Manufacturing and supply reliability.
4. Patient and prescriber adherence to the incumbent product.
5. Distribution access through specialty and community channels.
6. Any unlisted or non-Orange Book intellectual-property rights.

What is the Orange Book status of ENDARI?

ENDARI is approved under NDA 209053 and is subject to FDA Orange Book analysis for listed patents and exclusivity. The practical question for generic entrants is whether the current Orange Book contains patents that must be certified against in an ANDA.

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder receives proper notice, it may initiate patent litigation within 45 days. That filing can trigger a statutory stay of FDA approval for up to 30 months, subject to court and regulatory exceptions [3].

The relevant diligence points are:

• Current Orange Book patent listings for NDA 209053
• Patent expiration dates after patent-term adjustment
• Pediatric exclusivity attached to listed patents
• Whether a patent claims the approved method of use
• Whether a generic applicant can carve out the patented indication
• The timing and outcome of any Paragraph IV litigation
• Any settlement restricting commercial launch

A patent covering only a method of use may be vulnerable to a skinny-label strategy if the generic label omits the patented indication or dosing instructions. That strategy depends on the precise patent claims and FDA labeling requirements.

Which companies are challenging ENDARI?

Publicly documented commercial competition is more likely to arise from generic manufacturers than from biosimilar developers. L-glutamine is a small molecule and does not use the abbreviated biosimilars pathway under the Public Health Service Act.

Potential entrant categories include:

• Large generic manufacturers filing an ANDA
• Specialty-generic companies using a 505(b)(2) application
• Compounding pharmacies supplying non-equivalent formulations
• Nutraceutical manufacturers selling nonprescription L-glutamine
• Developers of pediatric or ready-to-use dosage forms

Nutraceutical L-glutamine products do not automatically substitute for ENDARI. They may differ in quality standards, labeling, dose accuracy, manufacturing controls, reimbursement, and FDA-approved indications.

No public commercial biosimilar challenge is relevant to ENDARI. The meaningful regulatory pathway is an ANDA or, for a reformulated product, a 505(b)(2) application.

What generic entry risks exist for ENDARI?

The risk is moderate to high after orphan exclusivity because the core active ingredient is off-patent and the marketed dosage form is technically simple. Risk is lower if method-of-use patents remain enforceable and are listed in the Orange Book with claims that prevent a commercially viable skinny label.

Generic launch scenarios

Scenario	Timing	Commercial effect
No viable patent challenge	Delayed until relevant patent expiry	Incumbent retains protection
Paragraph IV settlement	Launch date depends on agreement	Controlled erosion, often before full patent expiry
Skinny-label ANDA	Potentially before all patent expiry dates	Generic competes for non-carved-out use
Full-label generic approval	After patent barriers fall	Broad price and share pressure
505(b)(2) reformulation	Variable	Differentiated convenience or pediatric product
Authorized generic	At sponsor discretion	Can reduce third-party generic economics

The most exposed part of the brand is the basic 5-g powder packet. A differentiated pediatric or ready-to-use product could preserve premium pricing, but it would need measurable adherence, administration, or healthcare-utilization advantages.

How strong is the ENDARI patent estate?

The patent estate is stronger for disease-specific use than for the underlying molecule. L-glutamine has extensive prior art as an amino acid and nutritional ingredient. A patent strategy based solely on L-glutamine composition would be weak. Method-of-use claims, dosing claims, patient-selection claims, manufacturing specifications, and improved formulations are more defensible areas.

Patent-strength assessment

Patent subject	Relative strength
L-glutamine composition alone	Low
Sickle-cell-disease treatment method	Moderate, claim-dependent
Specific dosing regimen	Moderate
Pediatric administration method	Potentially moderate
Taste-masked formulation	Potentially strong if technically narrow and non-obvious
Ready-to-use suspension	Potentially strong, but stability data are critical
Packaging configuration	Narrow to moderate
Manufacturing control and particle specifications	Moderate if linked to product performance

Patent strength should be measured by enforceable claim scope, not the number of issued patents. Continuation patents can extend prosecution activity without materially increasing freedom-to-operate risk.

What licensing and commercial opportunities exist around ENDARI?

The clearest licensing opportunities concern technology that improves administration rather than the active ingredient itself.

Priority licensing targets

A rights holder could pursue:

• Taste-masking technology for amino-acid powders
• Pediatric flavor systems
• Low-moisture stick-pack manufacturing
• Dry powder reconstitution technology
• Unit-dose packaging platforms
• Controlled particle-size L-glutamine
• Stability-enhancing packaging
• Specialty-pharmacy adherence programs
• International distribution rights
• Co-development of 505(b)(2) formulations

A licensee would need to determine whether the technology creates a patentable distinction or only a commercial improvement. Formulation know-how, supplier exclusivity, and validated manufacturing processes may have commercial value even when patent protection is narrow.

No major publicly disclosed licensing transaction should be treated as the basis for valuation without transaction-specific documentation. ENDARI commercial economics are also difficult to assess because Emmaus has not provided the same level of public segment reporting as a large public pharmaceutical company.

How does ENDARI compare with competing sickle-cell drugs?

ENDARI competes with hydroxyurea, voxelotor where commercially available, crizanlizumab, transfusion programs, and emerging disease-modifying therapies. These products do not generally compete on the same formulation attributes.

Product	Modality	Administration	Formulation opportunity
ENDARI	L-glutamine oral powder	Twice-daily preparation	Taste, dosing, and convenience
Hydroxyurea	Oral small molecule	Capsules or liquid	Pediatric liquid and adherence
Crizanlizumab	Monoclonal antibody	Intravenous infusion	Infusion logistics, not excipient substitution
Voxelotor	Oral small molecule	Tablet	Tablet lifecycle management
Gene therapies	Cell and gene therapy	Specialized treatment centers	Manufacturing and delivery infrastructure

ENDARI’s principal competitive advantage is an oral, non-cytotoxic treatment option with a relatively simple supply chain. Its principal weakness is the high gram-dose burden and preparation requirement.

What is the FDA regulatory status of ENDARI?

ENDARI remains an FDA-approved product under NDA 209053 for reducing acute complications of sickle cell disease in adults and patients aged 5 years and older [1]. The product is regulated as a prescription drug, not as a dietary supplement, despite L-glutamine’s presence in the nutrition market.

A competing product positioned as an FDA-approved generic must meet pharmaceutical-equivalence and bioequivalence requirements through an ANDA. A reformulated product with a new dosage form, excipient system, or administration benefit may use the 505(b)(2) pathway, depending on the proposed labeling and reliance on FDA findings for the reference product [4].

Key Takeaways

• ENDARI is an L-glutamine oral powder supplied in 5-g packets.
• Its FDA labeling identifies no conventional excipient platform, making the product simple to manufacture but relatively easy to replicate.
• Orphan-drug exclusivity generally expired on July 7, 2024.
• The principal remaining barriers are method-of-use patents, Orange Book listings, Paragraph IV litigation, and manufacturing execution.
• L-glutamine has no biosimilar pathway; ANDA and 505(b)(2) applications are the relevant routes.
• The highest-value formulation opportunities are taste masking, flexible-dose packaging, dry reconstitution systems, and ready-to-use pediatric products.
• A generic launch would likely pressure the basic powder-packet product before materially affecting any differentiated lifecycle formulation.
• The strongest new intellectual-property opportunities are disease-specific methods, technically defined formulations, particle engineering, stability, and manufacturing controls.

FAQs

Can a generic manufacturer copy ENDARI without copying its brand formulation?

Yes. An ANDA applicant can seek approval for a pharmaceutically equivalent L-glutamine product without copying trade dress or proprietary packaging. It must satisfy FDA requirements for active ingredient, dosage form, strength, quality, and bioequivalence.

Is a flavored ENDARI product likely to receive new market exclusivity?

Not automatically. A flavored product may qualify for patent protection or a 505(b)(2) approval, but commercial exclusivity depends on the specific formulation, regulatory pathway, patent claims, and applicable FDA exclusivity provisions.

Are dietary L-glutamine products substitutes for ENDARI?

They are not regulatory equivalents. Dietary products generally do not carry ENDARI’s FDA-approved sickle-cell-disease indication, prescription controls, or equivalent product-specific approval requirements.

What is the most valuable excipient for an ENDARI reformulation?

No single excipient is likely to determine value. A validated combination of taste masking, rapid dispersion, dose flexibility, and pediatric acceptability would have greater commercial potential than a single sweetener or flavor.

Could ENDARI be replaced by an L-glutamine liquid?

Yes, technically and commercially, if the liquid achieves adequate stability, microbial control, dose uniformity, packaging performance, and patient acceptance. A dry powder for reconstitution may be more practical because aqueous L-glutamine systems create stability and shipping challenges.

References

1. U.S. Food and Drug Administration. (2017). ENDARI (L-glutamine) oral powder prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

5. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,609,676: Methods for treating sickle cell disease. USPTO.